SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

SPRY

Ars Pharmaceuticals Inc
NASDAQHealth Care

Latest close: 4.02 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 1, 2026Notice of sale · Form 144ERIC KARAS · Officer · $426.1KOpen the filing ↗
  2. Sep 30, 2026Notice of sale · Form 144ERIC KARAS · Officer · $431.6KOpen the filing ↗
  3. Sep 11, 2026Notice of sale · Form 144RICHARD LOWENTHAL · Officer, Director, 10% Stockholder · $177.0KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record51520 flagged findings
Reported transactions (Form 4)80since Jan 6, 2025
Corporate events (8-K)29since Mar 15, 2021

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

What the company does

biotech company

Source: Wikidata (CC0 1.0) · copied on Sep 3, 2026 · may not reflect recent changes.

Identity

Formerly traded as SBTX.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-15listing compliance noticerecentOpen filing ↗
    “…affect the trading price of our common stock. 102 In the past, following periods of volatility in the market price of a…”
    +1 more passage from the same document
    • “…a company’s securities, stockholders have often instituted class action securities litigation against those companies. Additionally,…”
  • 2026-05-15capital return (buybacks/dividends)recentOpen filing ↗
    “…the Company may terminate the ALK Collaboration Agreement with respect to all countries in the European Economic Area…”
    +1 more passage from the same document
    • “…Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,…”
  • 2026-05-15Department of Justice inquiryrecentOpen filing ↗
    “…which highlights a specific life-threatening safety risk, or comparable foreign strategies and requirements. The FDA or other…”
    +1 more passage from the same document
    • “…to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some…”
  • 2026-03-09listing compliance noticerecentOpen filing ↗
    “…price of our common stock. 103 Table of Contents In the past, following periods of volatility in the market price of a…”
    +1 more passage from the same document
    • “…a company’s securities, stockholders have often instituted class action securities litigation against those companies. Additionally,…”
  • 2026-03-09capital return (buybacks/dividends)recentOpen filing ↗
    “…the Company may terminate the ALK Collaboration Agreement with respect to all countries in the European Economic Area…”
    +1 more passage from the same document
    • “…Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,…”
  • 2026-03-09Department of Justice inquiryrecentOpen filing ↗
    “…which highlights a specific life-threatening safety risk, or comparable foreign strategies and requirements. The FDA or other…”
    +1 more passage from the same document
    • “…to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some…”
  • 2026-03-09merger or acquisition eventrecentOpen filing ↗
    “…Operations and Comprehensive (Loss) Income 125 Consolidated Statements of Stockholders’ Equity 126 Consolidated Statements of Cash…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 515)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

515 filings on record, the oldest from Oct 29, 20.

Listing the 25 most recent filings of the 515 on record.

8-Ks, explained

Stress1Structure18Governance10
  • Governance3 senior executive changes2026show all 3hide
    • Jul 17, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jul 7, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • May 13, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Sep 29, 25StructureTook on a new financial obligation+2 more in the same filing8-K 2.03 ↗
  • Structure4 material agreements entered2024 – 2025show all 4hide
  • Feb 22, 23StructureA material agreement was terminated+1 more in the same filing8-K 1.02 ↗
  • Dec 9, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Nov 8, 22StructureCompleted an acquisition or disposal+8 more in the same filing8-K 2.01 ↗
  • Oct 27, 22StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Sep 30, 22StructureA material agreement was terminated+2 more in the same filing8-K 1.02 ↗
  • Sep 2, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Jul 21, 22StressRestructuring plan with committed costs+4 more in the same filing8-K 2.05 ↗
  • May 6, 22StructureA material agreement was terminated8-K 1.02 ↗
  • Mar 17, 22GovernanceA senior executive left or was appointed8-K 5.02 ↗

2 older filings not shown

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • RA Capital Management, L.P.11.1%Sep 29, 25SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Deerfield Management Company, L.P.7.8%Jul 30, 25SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Rubric Capital Management LP8.1%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BlackRock, Inc.5.3%Jun 30, 26SCHEDULE 13G ↗2 earlier filings
  • Millennium Management LLC2.5%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Oct 1, ERIC KARAS filed notice of intent to sell up to $426K. That is about 0.10% of shares outstanding.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

No sale of theirs is on record yet in Form 4; the 90-day window is still open.

View notice (Form 144) ↗+9 more recent notices

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Jun 12, 26Sell$34KAlexander A FitzpatrickChief Legal Officer↗
  • Jun 12, 26Sell$250KEric KarasChief Commercial Officer↗
  • Nov 13, 25Sell$190KBrian DorseyChief Operating Officer↗
  • Nov 12, 25Sell$267KJustin ChakmaChief Business Officer↗
  • Nov 12, 25Sell$1.2MJustin ChakmaChief Business Officer↗
  • Aug 21, 25Sell$188KKathleen D. ScottChief Financial Officer↗
  • Aug 21, 25Sell$724KRichard E LowenthalPRESIDENT AND CEO↗
  • Aug 20, 25Sell$531KSarina TanimotoCHIEF MEDICAL OFFICER↗
  • Aug 19, 25Sell$173KSarina TanimotoCHIEF MEDICAL OFFICER↗
  • Jul 1, 25Sell$255KEric KarasChief Commercial Officer↗
  • Jun 27, 25Sell$6.8MJames E Flynn↗
  • Jun 27, 25Sell$6.8MJames E Flynn↗

There are 9 more transactions in this stretch.

Stock compensation, tax and giftsshow the 19 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jun 12, 26Compensation$38KEric KarasChief Commercial Officer↗
  • Nov 13, 25Compensation$14KBrian DorseyChief Operating Officer↗
  • Nov 12, 25Giftamount n/aPratik Shah↗
  • Nov 12, 25Giftamount n/aPratik Shah↗
  • Nov 12, 25Compensation$25KJustin ChakmaChief Business Officer↗
  • Aug 21, 25Compensation$19KKathleen D. ScottChief Financial Officer↗
  • Jul 1, 25Compensation$23KEric KarasChief Commercial Officer↗
  • Jun 18, 25Compensation$23KEric KarasChief Commercial Officer↗
  • May 20, 25Compensation$75KKathleen D. ScottChief Financial Officer↗
  • May 20, 25Compensation$121KBRENT L SAUNDERS↗
  • May 20, 25Compensation$558KAlexander A FitzpatrickChief Legal Officer↗
  • Apr 7, 25Compensation$109KLaura Shawver↗
  • Apr 7, 25Compensation$133KLaura Shawver↗
  • Mar 20, 25Compensation$15KEric KarasChief Commercial Officer↗
  • Mar 6, 25Compensation$241KLaura Shawver↗
  • Mar 5, 25Compensation$2KLaura Shawver↗
  • Feb 3, 25Compensation$29KLaura Shawver↗
  • Feb 3, 25Compensation$199KLaura Shawver↗
  • Jan 6, 25Compensation$158KLaura Shawver↗

The full record holds 312 transactions and goes back to Nov 9, 22.

Its sector and its market

Ars Pharmaceuticals Inc among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Ars Pharmaceuticals Inc, the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Ars Pharmaceuticals Inc in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
515 documents on file, from Oct 29, 2020 to Oct 5, 2026.
Company description
Wikidata, read on Sep 3, 2026.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.